BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

809 related articles for article (PubMed ID: 11326284)

  • 1. Gene therapy restores vision in a canine model of childhood blindness.
    Acland GM; Aguirre GD; Ray J; Zhang Q; Aleman TS; Cideciyan AV; Pearce-Kelling SE; Anand V; Zeng Y; Maguire AM; Jacobson SG; Hauswirth WW; Bennett J
    Nat Genet; 2001 May; 28(1):92-5. PubMed ID: 11326284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness.
    Acland GM; Aguirre GD; Bennett J; Aleman TS; Cideciyan AV; Bennicelli J; Dejneka NS; Pearce-Kelling SE; Maguire AM; Palczewski K; Hauswirth WW; Jacobson SG
    Mol Ther; 2005 Dec; 12(6):1072-82. PubMed ID: 16226919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation.
    Aguirre GK; Komáromy AM; Cideciyan AV; Brainard DH; Aleman TS; Roman AJ; Avants BB; Gee JC; Korczykowski M; Hauswirth WW; Acland GM; Aguirre GD; Jacobson SG
    PLoS Med; 2007 Jun; 4(6):e230. PubMed ID: 17594175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis.
    Jacobson SG; Boye SL; Aleman TS; Conlon TJ; Zeiss CJ; Roman AJ; Cideciyan AV; Schwartz SB; Komaromy AM; Doobrajh M; Cheung AY; Sumaroka A; Pearce-Kelling SE; Aguirre GD; Kaushal S; Maguire AM; Flotte TR; Hauswirth WW
    Hum Gene Ther; 2006 Aug; 17(8):845-58. PubMed ID: 16942444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success.
    Jacobson SG; Aleman TS; Cideciyan AV; Sumaroka A; Schwartz SB; Windsor EA; Traboulsi EI; Heon E; Pittler SJ; Milam AH; Maguire AM; Palczewski K; Stone EM; Bennett J
    Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6177-82. PubMed ID: 15837919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In utero gene therapy rescues vision in a murine model of congenital blindness.
    Dejneka NS; Surace EM; Aleman TS; Cideciyan AV; Lyubarsky A; Savchenko A; Redmond TM; Tang W; Wei Z; Rex TS; Glover E; Maguire AM; Pugh EN; Jacobson SG; Bennett J
    Mol Ther; 2004 Feb; 9(2):182-8. PubMed ID: 14759802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.
    Cideciyan AV; Aleman TS; Boye SL; Schwartz SB; Kaushal S; Roman AJ; Pang JJ; Sumaroka A; Windsor EA; Wilson JM; Flotte TR; Fishman GA; Heon E; Stone EM; Byrne BJ; Jacobson SG; Hauswirth WW
    Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15112-7. PubMed ID: 18809924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.
    Hauswirth WW; Aleman TS; Kaushal S; Cideciyan AV; Schwartz SB; Wang L; Conlon TJ; Boye SL; Flotte TR; Byrne BJ; Jacobson SG
    Hum Gene Ther; 2008 Oct; 19(10):979-90. PubMed ID: 18774912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RPE65: role in the visual cycle, human retinal disease, and gene therapy.
    Cai X; Conley SM; Naash MI
    Ophthalmic Genet; 2009 Jun; 30(2):57-62. PubMed ID: 19373675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis.
    Pang JJ; Chang B; Kumar A; Nusinowitz S; Noorwez SM; Li J; Rani A; Foster TC; Chiodo VA; Doyle T; Li H; Malhotra R; Teusner JT; McDowell JH; Min SH; Li Q; Kaushal S; Hauswirth WW
    Mol Ther; 2006 Mar; 13(3):565-72. PubMed ID: 16223604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement.
    Cideciyan AV; Jacobson SG; Beltran WA; Sumaroka A; Swider M; Iwabe S; Roman AJ; Olivares MB; Schwartz SB; Komáromy AM; Hauswirth WW; Aguirre GD
    Proc Natl Acad Sci U S A; 2013 Feb; 110(6):E517-25. PubMed ID: 23341635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis.
    Li X; Li W; Dai X; Kong F; Zheng Q; Zhou X; Lü F; Chang B; Rohrer B; Hauswirth WW; Qu J; Pang JJ
    Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):7-15. PubMed ID: 21169527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer.
    Bennicelli J; Wright JF; Komaromy A; Jacobs JB; Hauck B; Zelenaia O; Mingozzi F; Hui D; Chung D; Rex TS; Wei Z; Qu G; Zhou S; Zeiss C; Arruda VR; Acland GM; Dell'Osso LF; High KA; Maguire AM; Bennett J
    Mol Ther; 2008 Mar; 16(3):458-65. PubMed ID: 18209734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using the NAFX to measure the effectiveness over time of gene therapy in canine LCA.
    Jacobs JB; Dell'Osso LF; Wang ZI; Acland GM; Bennett J
    Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4685-92. PubMed ID: 19458334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA).
    Pang JJ; Chang B; Hawes NL; Hurd RE; Davisson MT; Li J; Noorwez SM; Malhotra R; McDowell JH; Kaushal S; Hauswirth WW; Nusinowitz S; Thompson DA; Heckenlively JR
    Mol Vis; 2005 Feb; 11():152-62. PubMed ID: 15765048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy.
    Cideciyan AV
    Prog Retin Eye Res; 2010 Sep; 29(5):398-427. PubMed ID: 20399883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog.
    Narfström K; Katz ML; Bragadottir R; Seeliger M; Boulanger A; Redmond TM; Caro L; Lai CM; Rakoczy PE
    Invest Ophthalmol Vis Sci; 2003 Apr; 44(4):1663-72. PubMed ID: 12657607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.
    Le Meur G; Stieger K; Smith AJ; Weber M; Deschamps JY; Nivard D; Mendes-Madeira A; Provost N; Péréon Y; Cherel Y; Ali RR; Hamel C; Moullier P; Rolling F
    Gene Ther; 2007 Feb; 14(4):292-303. PubMed ID: 17024105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological Amelioration of Cone Survival and Vision in a Mouse Model for Leber Congenital Amaurosis.
    Li S; Samardzija M; Yang Z; Grimm C; Jin M
    J Neurosci; 2016 May; 36(21):5808-19. PubMed ID: 27225770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection.
    Jacobson SG; Acland GM; Aguirre GD; Aleman TS; Schwartz SB; Cideciyan AV; Zeiss CJ; Komaromy AM; Kaushal S; Roman AJ; Windsor EA; Sumaroka A; Pearce-Kelling SE; Conlon TJ; Chiodo VA; Boye SL; Flotte TR; Maguire AM; Bennett J; Hauswirth WW
    Mol Ther; 2006 Jun; 13(6):1074-84. PubMed ID: 16644289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.